🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Having lots of fun with my host, Dr. Ozren Bogdanovic, during my visit to the Andalusian Centre for Developmental Biology in Sevilla 🇪🇸.

Excited to share ideas and connect this Friday with my colleagues in Ottawa!

Excited to share our new Molecular Systems Biology paper! We developed SIMPL2, innovative tool for studying protein interactions - rapid, inexpensive, and highly sensitive. It’s a game-changer for drug discovery, especially for targeting ‘undruggable’ proteins! Donnelly Centre

My lab developed SIMPL2, a tool to study protein-protein interactions - key for understanding diseases and creating medicines. It accelerates drug discovery for undruggable targets.

Thrilled to share our latest work in Mol Syst Biol, featuring SIMPL2, a game-changing tool for detecting protein-protein interactions with unmatched sensitivity and specificity. Will be featured on the Feb 2025 cover of Mol Syst Biol! #DrugDiscovery #Innovation #SIMPL2

Ako si sportaš i gubiš 30 razlike, pravi sportaš će prići protivniku, stisnuti mu ruku i reći: ‘Svaka čast, bolji si. Ja još trebam pojesti puno žganaca da te dostignem.’ A ne izmišljati gluposti i tražiti izgovore….

Cheers to 2025: love, laughter, and common sense leading the way 🥂

Pravi sportaš čestita suparniku na pobjedi! Just saying… 😅

The spread of health misinformation and disinformation poses a serious threat to public health. How can we respond to the danger and combat the tide of misinformation and disinformation to protect public health? Find out more in our latest Editorial: hubs.li/Q032YWZ40

A study co-led by University of Toronto researchers + Insilico Medicine has demonstrated for the first time the potential of #quantum + #AI to transform the drug discovery pipeline. Follow the link to learn more or read on below. temertymedicine.utoronto.ca/news/u-t-resea…

Excited to share our latest breakthrough in Nature Biotechnology! Together with Alán Aspuru-Guzik, Alex Zhavoronkov, and Insilico Medicine, we used quantum computing and AI to design molecules targeting KRAS-one of cancer's toughest challenges- big step forward in drug discovery!

Thrilled to share our milestone collaboration with Alán Aspuru-Guzik, Alex Zhavoronkov, Insilico Medicine, and our teams at UofT and the UAE! Using quantum computing to design KRAS inhibitors brings the future of drug discovery closer. Excited for what’s next!

Excited to join the Ontario Institute for Cancer Research (OICR) as an Affiliate! Looking forward to collaborating on innovative cancer research projects using our live-cell technologies to target undruggable cancer proteins. Ontario Institute for Cancer Research (OICR) Donnelly Centre Temerty Medicine

Nature Biotechnology Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) Alan Aspuru-Guzik Igor Stagljar Insilico Medicine U of T Department of Computer Science Chemistry at UofT Donnelly Centre CIFAR Stanford University St. Jude Research Temerty Medicine That Investor

Honored to have our work on a novel split intein-luciferase system featured on the cover of Molecular Systems Biology! 🚀 Grateful to my amazing team! Mol Syst Biol

Excited to see our work featured on the cover! Huge thanks to Mol Syst Biol and my team! 🚀🔬

After CNN, now we’re in Psychology Today! Our latest work on using AI and quantum computing to discover new cancer drugs has been featured in this prestigious journal. A great honor for our team and collaborators, and a testament to pushing the boundaries of science! 🚀💡

Iiii liiikkeeee 🙃

This morning I spoke on “Dobro jutro Hrvatska” (“Good morning Croatia) about cancer, AI in drug discovery & precision medicine. Take-home message: The future of medicine is where biology meets AI. We’re not imagining cures anymore. We’re building them. Thanks HRT 🇭🇷

THRILLED TO LAUNCH "DISEASE AND THERAPEUTICS", a bold new Elsevier journal I’ll lead as Editor-in-Chief 💡 breakthrough preclinical & clinical research across cancer, aging, neurology & more Backed by a world-class board from academia & pharma. Submissions open soon!